Study Description
This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.
This is a 24-week, prospective, open-label, multi-center, single-arm, observational, post-marketing surveillance study under routine clinical practice and does not impose a therapy, visit, or assessment. The study design was approved by the Korean health authority. The purpose of this study is not to answer scientific hypotheses, but to describe the incidences of all potential adverse events (AEs), serious adverse events (SAEs), and unexpected AEs not listed in the local label information occurring in Korean patients under routine clinical practice following the approved local label information.
Interventions
Xolair
Eligibility Criteria
Inclusion Criteria:
Adults aged ≥18 years
Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS)
Patients prescribed with Xolair® as per the locally approved label information.
Patients who provide written informed consent to participate in the study
Exclusion Criteria:
Patients who do not provide consent to participate in the study
Patients participating in other clinical trial
Contraindications listed in the locally approved label information of Xolair®
Hypersensitivity to the active ingredient or any other ingredient of Xolair®
Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)
Study Location
Novartis Investigative Site
Recruiting
Bundang Gu,Gyeonggi Do,13620,Korea, Republic of
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.